Cargando…

Review article: vascular effects of PPARs in the context of NASH

BACKGROUND: Peroxisome proliferator‐activated receptors (PPARs) are ligand‐activated transcription factors known to regulate glucose and fatty acid metabolism, inflammation, endothelial function and fibrosis. PPAR isoforms have been extensively studied in metabolic diseases, including type 2 diabete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guixé‐Muntet, Sergi, Biquard, Louise, Szabo, Gyongyi, Dufour, Jean‐François, Tacke, Frank, Francque, Sven, Rautou, Pierre‐Emmanuel, Gracia‐Sancho, Jordi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328268/ https://www.ncbi.nlm.nih.gov/pubmed/35661191 http://dx.doi.org/10.1111/apt.17046

Ejemplares similares

Advances in therapeutic options for portal hypertension
por: Vilaseca, Marina, et al.
Publicado: (2018)

4 in 1: Antibody‐free protocol for isolating the main hepatic cells from healthy and cirrhotic single rat livers
por: Fernández‐Iglesias, Anabel, et al.
Publicado: (2018)

Regression of portal hypertension: underlying mechanisms and therapeutic strategies
por: Selicean, Sonia, et al.
Publicado: (2021)

Mechanobiology of portal hypertension
por: Felli, Eric, et al.
Publicado: (2023)

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
por: Gibert-Ramos, Albert, et al.
Publicado: (2021)

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease
por: Biquard, Louise, et al.
Publicado: (2020)

Immune and inflammatory pathways in NASH
por: Ganz, Michal, et al.
Publicado: (2013)

Nuclear deformation mediates liver cell mechanosensing in cirrhosis
por: Guixé-Muntet, Sergi, et al.
Publicado: (2020)

Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans
por: Jin, Chaonan, et al.
Publicado: (2022)

Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism
por: Gracia‐Sancho, Jordi, et al.
Publicado: (2019)

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
por: de Mesquita, Fernanda Cristina, et al.
Publicado: (2017)

New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease
por: Maeso-Díaz, Raquel, et al.
Publicado: (2019)

Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
por: Guarino, Maria, et al.
Publicado: (2020)

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

Surveillance for Hepatocellular Carcinoma in Patients with NASH
por: Kolly, Philippe, et al.
Publicado: (2016)

Identifying High-Risk NASH Patients: What We Know so Far
por: Schulz, Marten, et al.
Publicado: (2020)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

Somatic mutant clone screening: scan for novel NASH target genes in mouse liver
por: Lan, Tian, et al.
Publicado: (2023)

NASH-related increases in plasma bile acid levels depend on insulin resistance
por: Grzych, Guillaume, et al.
Publicado: (2020)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH
por: Cariello, Marica, et al.
Publicado: (2021)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Erratum for the Research Article: “Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC”
Publicado: (2023)

Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
por: Sandoval‐Rodriguez, Ana, et al.
Publicado: (2020)

Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver
por: Lee, Samuel M., et al.
Publicado: (2021)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism?
por: Lambrecht, Joeri, et al.
Publicado: (2020)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Genistein Modulated Lipid Metabolism, Hepatic PPARγ, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH)
por: Pummoung, Sudaporn, et al.
Publicado: (2020)

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model
por: Liu, Linfu, et al.
Publicado: (2020)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
por: Hayashi, Momoko, et al.
Publicado: (2023)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Unboxing the cell-type specific contribution of endoplasmic reticulum stress to NASH pathophysiology—myeloid X-box-binding protein 1 as a driver of steatohepatitis and fibrosis
por: Horn, Paul, et al.
Publicado: (2022)

Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review
por: Farrugia, Marwin A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qov7sslgp41u2a9obrt6qnbbd2